Remember Cambridge Analytica? What to know about the $8B US lawsuit against Meta's board

An $8 billion investors' class-action lawsuit against Mark Zuckerberg and other Meta board members, stemming from the 2018 Cambridge Analytica data scandal, is set to begin. Plaintiffs allege the data harvesting violated a 2012 FTC agreement and seek over $8 billion in damages, including reimbursement for the $5 billion FTC fine, further claiming Zuckerberg sold shares, pocketing over $1 billion, based on anticipated stock decline. This high-profile trial, featuring testimony from current and former executives, underscores significant corporate governance and data privacy litigation risks for Meta and its leadership.

Analysis

Meta is facing a significant legal and governance challenge with the commencement of an $8 billion investor class-action lawsuit in Delaware's Court of Chancery. The suit, which follows years of litigation and prior settlements including a $5 billion FTC fine and a $725 million user settlement, alleges that the board, including CEO Mark Zuckerberg and former COO Sheryl Sandberg, breached its fiduciary duties related to the Cambridge Analytica data scandal by violating a 2012 FTC consent decree. Plaintiffs are seeking to have the defendants reimburse Meta for over $8 billion in fines and costs. The trial introduces two primary risks: a direct challenge to the board's oversight and a specific allegation of insider trading against Zuckerberg, who plaintiffs claim sold over $1 billion in shares based on non-public information about the impending scandal. The defense refutes these claims, arguing Meta was deceived by Cambridge Analytica and that Zuckerberg's sales were conducted under a pre-approved trading plan. The involvement of high-profile current and former directors, coupled with allegations of poor record-keeping practices, places Meta's corporate governance framework under intense scrutiny, with a potential ruling on director liability setting a major precedent.

Key Decisions for Investors

• Investors should monitor the trial's outcome closely, as a ruling holding directors personally liable for reimbursing the company could establish a significant governance overhang and impact long-term valuation.
• Expect heightened stock volatility and negative headline risk as high-profile executives like Mark Zuckerberg and Sheryl Sandberg testify, which may create short-term trading opportunities or necessitate risk management.
• The allegations of insider trading against the CEO are a material risk to investor confidence; the evidence presented regarding his stock trading plan should be scrutinized, as an adverse finding could be more damaging to sentiment than the historical data privacy issues.